Literature DB >> 7516210

Limited effectiveness of FK506 administration for ongoing rejection in heterotopic rat heart transplantation.

K Hisatomi1, T Sato, M Nishimi, A Hirano, T Isomura, S Aoyagi, K Kosuga, K Ohishi.   

Abstract

A comparison was made of the histological findings for myocardial tissue of heterotopic transplanted rat hearts administered with FK506. ACI rats were used as donors and Lewis rats as recipients. FK506 was used for 6 days except for group I (control group). Group II received 0.32 mg/kg/day of FK506 from the day of operation while group III was given the same dosage from the 4th day after transplantation. Group IV was given 1.28 mg/kg/day of the agent from the day of grafting and group V received the same dose from the 4th postoperative day. The graft survival time was longer for all groups given FK506, but was significantly longer only for groups administered with FK506 from the day of operation. Histological studies performed 10 and 20 days after transplantation showed that a moderate rejection was seen in about half of the grafts receiving FK506 from the 4th day after grafting. An ultrastructural study of these cases showed that infiltrating large lymphocytes still remained in the interstitial tissues and that the cytoplasmic organelles of the myocytes had been focally destroyed. These results suggest that, although FK506 suppressed any further rejection, the effect might be limited and the myocardial changes of the cardiac graft might persist even after administration for ongoing rejection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516210     DOI: 10.1007/bf02032897

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  12 in total

1.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation.

Authors:  M E Billingham; N R Cary; M E Hammond; J Kemnitz; C Marboe; H A McCallister; D C Snovar; G L Winters; A Zerbe
Journal:  J Heart Transplant       Date:  1990 Nov-Dec

2.  Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction.

Authors:  B E Bierer; S L Schreiber; S J Burakoff
Journal:  Transplantation       Date:  1990-06       Impact factor: 4.939

3.  FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats.

Authors:  N Murase; D G Kim; S Todo; D V Cramer; J Fung; T E Starzl
Journal:  Transplantation       Date:  1990-11       Impact factor: 4.939

4.  Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats.

Authors:  T Ochiai; K Nakajima; M Nagata; S Hori; T Asano; K Isono
Journal:  Transplantation       Date:  1987-12       Impact factor: 4.939

5.  Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.

Authors:  S Sawada; G Suzuki; Y Kawase; F Takaku
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

6.  Studies of the effects of FK506 on renal allografting in the beagle dog.

Authors:  T Ochiai; M Nagata; K Nakajima; T Suzuki; K Sakamoto; K Enomoto; Y Gunji; T Uematsu; T Goto; S Hori
Journal:  Transplantation       Date:  1987-12       Impact factor: 4.939

7.  Improved technique of heart transplantation in rats.

Authors:  K Ono; E S Lindsey
Journal:  J Thorac Cardiovasc Surg       Date:  1969-02       Impact factor: 5.209

8.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

9.  Liver, kidney, and thoracic organ transplantation under FK 506.

Authors:  S Todo; J J Fung; T E Starzl; A Tzakis; A J Demetris; R Kormos; A Jain; M Alessiani; S Takaya; R Shapiro
Journal:  Ann Surg       Date:  1990-09       Impact factor: 12.969

10.  Clinical trial of FK 506 immunosuppression in adult cardiac transplantation.

Authors:  J M Armitage; R L Kormos; S Morita; J Fung; G C Marrone; R L Hardesty; B P Griffith; T E Starzl
Journal:  Ann Thorac Surg       Date:  1992-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.